- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07724548
Comparison Between Virtual vs in Person on Treatment Follow-up Visits of Radiotherapy
Transforming On-Treatment Follow-Up Care: A Randomized Controlled Trial of Virtual Versus In-Person Visits Evaluating Clinical Outcomes, Patient-Reported Measures, and Telehealth Implementation
Studieoversikt
Status
Forhold
Detaljert beskrivelse
Telemedicine and telehealth services, operationally defined as patient-provider interactions conducted through telecommunication technologies, have experienced widespread integration across diverse medical specialties. Prior to the onset of the coronavirus disease 2019 (COVID-19) pandemic, numerous clinical disciplines had adopted telemedicine modalities to enhance healthcare accessibility and improve patient convenience. The COVID-19 pandemic and its aftermath have precipitated an unprecedented acceleration in the adoption of telehealth services, profoundly reshaping healthcare delivery paradigms across multiple disciplines.
As of 2025, Pakistan continues to grapple with a substantial cancer burden, with more than 185,000 new cases and over 125,000 cancer-related deaths reported annually. Despite ongoing efforts to improve awareness, early detection, and treatment accessibility, major challenges persist-particularly regarding healthcare access in rural regions and the financial burden associated with cancer treatment. For patients undergoing primary treatment, the costs of travel, accommodation, and sustenance during treatment and follow-up visits constitute significant barriers. These economic constraints frequently result in missed appointments and treatment discontinuation, thereby compromising the effectiveness of established therapeutic protocols.
Addressing these barriers necessitates a multifaceted approach, including the strategic expansion of telemedicine services. Telehealth can serve as a vital tool to bridge gaps in cancer care accessibility, ensuring that patients receive timely and continuous treatment regardless of geographic location or socioeconomic status.
Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKMCH&RC) is a leading institution in Pakistan, delivering comprehensive oncologic care to a large patient population. In 2024 alone, approximately 83,000 patients received radiotherapy in neoadjuvant, adjuvant, or palliative settings, underscoring the hospital's pivotal role in cancer management. As a high-volume cancer center, effective coordination of follow-up appointments and the maintenance of accurate clinical documentation are essential tasks that require seamless collaboration between patients and healthcare professionals.
Patients undergoing radiation therapy at SKMCH&RC were consecutively recruited and randomly assigned to either a hybrid follow-up group, receiving one virtual and one in-person appointment, or a control group receiving only in-person follow-ups. Clinical and demographic information was obtained from patient records. Following each visit, patients completed an anonymous, validated questionnaire survey assessing satisfaction, communication, and convenience. Additional logistical data, including appointment adherence, visit duration, and any technical difficulties during virtual visits, were systematically documented. All collected data were anonymized and stored securely to maintain confidentiality and support robust analysis of telehealth integration in on-treatment care.
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: Anusha Haider, MBBS
- Telefonnummer: 4072 03244534247
- E-post: anushahaider@skm.org.pk
Studer Kontakt Backup
- Navn: Sadia Anjum, MBBS
- Telefonnummer: 4072 03280117652
- E-post: sadianjum@skm.org.pk
Studiesteder
-
-
Punjab Province
-
Lahore, Punjab Province, Pakistan
- Rekruttering
- Shaukat Khanum Memorial Cancer hospital & Research Centre
-
Ta kontakt med:
- Farah Asif, MBBS
- Telefonnummer: 4280 04235905000
- E-post: crc3@skm.org.pk
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Patients who are 18 years and above.
- All patients who are undergoing radiotherapy (>5 fractions).
- Capacity to provide informed consent for participation in the study.
Exclusion Criteria:
- Patients below 18 years
- Unable to provide informed consent for participation in the study.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
|---|
|
Inperson followup visits
Group A involves weekly in person followup visits in radiation department undergoing radiotherapy.
|
|
Hybrid virtual & inperson radiotherpay followup
Group B involves hybrid group with alternating 1 virtual and 1 in person followup visits in radiation department undergoing radiotherapy.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Outcomes of virtual vs in person on treatment of follow-up radiotherapy visits through structured questionnaire
Tidsramme: 4 weeks
|
To evaluate the implementation of virtual and in person follow-up visits thereby accessing and comparing patient satisfaction with both modalities through structured questionnaire providing insights into clinical utility and overall acceptability of telehealth integration during active cancer treatment.
|
4 weeks
|
Samarbeidspartnere og etterforskere
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Latif A, Usmani S, Sheikh A, et al. Bridging oncology gaps with telemedicine in low-resource settings. J Glob Oncol. 2023;9:1-8.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- IRB-25-1
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .